Pharma's Direct-To-Patient Wave Hits Novartis Next

Benzinga_recent_news09-30

The Pharmaceutical Research and Manufacturers of America (PhRMA) outlined initiatives to bolster U.S. manufacturing, ease patient costs, and improve access to medicine. The trade group emphasized that...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2571351075?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/09/29/Novartis.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2025-09-30 02:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2571351075","market":"us","top_or_hot":-1,"title":"Pharma's Direct-To-Patient Wave Hits Novartis Next","media":"Benzinga_recent_news","content":"<div>\n<p>The Pharmaceutical Research and Manufacturers of America (PhRMA) outlined initiatives to bolster U.S. manufacturing, ease patient costs, and improve access to medicine.\nThe trade group emphasized that...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/25/09/47925052/pharmas-direct-to-patient-wave-hits-novartis-next\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pharma's Direct-To-Patient Wave Hits Novartis Next</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPharma's Direct-To-Patient Wave Hits Novartis Next\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-09-30 02:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/health-care/25/09/47925052/pharmas-direct-to-patient-wave-hits-novartis-next><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The Pharmaceutical Research and Manufacturers of America (PhRMA) outlined initiatives to bolster U.S. manufacturing, ease patient costs, and improve access to medicine.\nThe trade group emphasized that...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/25/09/47925052/pharmas-direct-to-patient-wave-hits-novartis-next\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0208291251.USD","symbol_name":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/25/09/47925052/pharmas-direct-to-patient-wave-hits-novartis-next","article_id":"2571351075","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/09/29/Novartis.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/09/47925052/pharmas-direct-to-patient-wave-hits-novartis-next","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2571351075","pubTimestamp":1759168860,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"The Pharmaceutical Research and Manufacturers of America (PhRMA) outlined initiatives to bolster U.S. manufacturing, ease patient costs, and improve access to medicine.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4588":"碎股","DTP":"DTE Energy Company","BK4585":"ETF&股票定投概念","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","LU0211331839.USD":"FRANKLIN MUTUAL GLB DISCOVERY \"A\" (USD) ACC","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","BK4578":"CAR-T","NVS":"诺华","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4532":"文艺复兴科技持仓","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4007":"制药"},"translate_title":"制药公司直接面向患者的浪潮接下来袭击诺华","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DTP":1,"NVS":1},"content_text":"The Pharmaceutical Research and Manufacturers of America (PhRMA) outlined initiatives to bolster U.S. manufacturing, ease patient costs, and improve access to medicine.\nThe trade group emphasized that these efforts reflect the biopharmaceutical industry’s long-term commitment to American patients and workers.\nPhRMA member companies plan to make what the organization described as historic investments in U.S.-based manufacturing and infrastructure.\nAlso Read: Your AstraZeneca Medicine Could Be Cheaper As Much As 70%\nIn addition, they will expand financial assistance programs for millions of insured and underinsured patients and launch a new online platform to simplify access to direct purchase programs and support resources.\nA major piece of this initiative is AmericasMedicines.com, a website scheduled to go live in January 2026. The site is designed to connect patients directly with manufacturer purchase options and patient assistance programs.\nPhRMA said the goal is to reduce reliance on pharmacy benefit managers (PBMs) and other intermediaries, which often collect large rebates while patients face higher out-of-pocket expenses.\nThe trade group noted that President Donald Trump encouraged manufacturers to allow patients and employers to purchase medicines directly at lower costs.\nSeveral companies have begun offering programs with transparent pricing and no hidden fees. AmericasMedicines.com will aggregate these offerings, making it easier for patients to find and access medications prescribed by their doctors.\nOn Monday, Novartis AG (NYSE: NVS) provided a tangible example of this trend, announcing plans to launch a direct-to-patient (DTP) platform in the U.S., effective November 1, 2025, offering cash-paying patients prescribed Cosentyx (secukinumab) the option to purchase it at a 55% discount off the list price.\nCosentyx, Novartis’ top-selling product in the U.S., is a biologic that is FDA-approved for multiple immune-mediated inflammatory diseases, including psoriasis, hidradenitis suppurativa, and psoriatic arthritis.\nThrough the DTP platform, Novartis will offer Cosentyx to American patients at a price that reflects the average savings that insurers and pharmacy benefit managers receive.\nPhRMA members are committing $500 billion to new U.S. infrastructure projects alongside the website launch.\nThese investments are expected to generate $1.2 trillion in economic output and create over 100,000 jobs, including 25,000 directly within the biopharmaceutical sector.\nIndustry leaders stressed that such investments rely on a stable policy environment without new tariffs or government price controls, warning that tariffs on medicines would redirect funds away from domestic growth and research.\nPhRMA also highlighted ongoing patient support programs. According to the organization, member companies provide financial assistance to 10 million Americans annually.\nRead Next:\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2571351075","isCrawlerRequest":true}